Engine Biosciences Raises $10 Million for AI Drug Discovery from Asian/US Investors

Engine Biosciences, a San Francisco-Singapore startup, raised $10 million in seed capital to develop its artificial intelligence/genomics drug development platform. The company claims its platform, which combines massively parallel biological experimentation with artificial intelligence, provides faster and deeper understanding of biologic interactions, offering new insights into drug development. The seed round was co-led by California 's DHVC and Shanghai 's 6 Dimensions Capital (the entity formed by a merger between Frontline Bioventures and WuXi Healthcare Ventures). More details.... Share this with colleagues: // //